The Programme

Official Launch of "2023 Set Sail for GBA - Scheme for Financial Leaders of Tomorrow" Shenzhen-Hong Kong Youth Internship Programme in Finance

Retrieved on: 
Tuesday, June 6, 2023
SBS, Insurance, Fintech, Plan, Employment, CITIC, MH, Convention center, Life, Financial services, JP, The Programme, GBA, Culture, GBM, Former Central Government Offices, HKSAR, University, Social skills, Taiping, Risk management, Government, Treasury, Student, Data analysis, Work, Global Financial Leaders' Investment Summit, Financial Services and the Treasury Bureau, GBS, Guangdong–Hong Kong–Macao Greater Bay Area, Liaison Office, Property Owned by the Central People's Government in the Hong Kong Special Administrative Region, City, FSTB, Mathematics, YAN, Seemabaddha, Central government, Economics, Tutoring, Creative industries

HONG KONG, June 6, 2023 - (ACN Newswire) - As the global financial centre of our country, Hong Kong has nurtured generations of financial leaders.

Key Points: 
  • HONG KONG, June 6, 2023 - (ACN Newswire) - As the global financial centre of our country, Hong Kong has nurtured generations of financial leaders.
  • The Financial Services and the Treasury Bureau (FSTB) of the Hong Kong Special Administrative Region (HKSAR) Government, the Shenzhen Municipal Financial Regulatory Bureau (SMFRB) and the Greater Bay Area Homeland Youth Community Foundation (the Foundation) are co-organising the "2023 Set Sail for GBA - Scheme for Financial Leaders of Tomorrow" - Shenzhen-Hong Kong Youth Internship Programme (the Programme).
  • The Programme supports students from universities in Hong Kong to explore the financial market of the Greater Bay Area (GBA) through a 6-week internship in financial organisations in Shenzhen, as well as a 4-day/3-night trip to the GBA.
  • The Programme enables our talented youth from local universities to gain greater understanding of the GBA financial market, experience the way of life and culture in the GBA, and develop their social network.

Dah Sing Bank and Friends of the Earth (HK) Jointly Present Retail and E-Commerce ESG Forum for SMEs

Retrieved on: 
Wednesday, September 21, 2022
Online, Grade (consulting), United Nations Sustainable Development Group, Carbon, Time, Forum, ESG, NMG, Dah Sing Bank, Goal, Challenge, Senior, Acquisition, Partnership, Industry, Climate change, Environment, Content, Government, Bank, Investment, Hong Kong Stock Exchange, Program, CESGA, SME, Friends of the Earth, The Programme, HK, Food safety, Solution, Retail, Guangdong-Hong Kong-Macau Greater Bay Area, Sector, Friends, Awareness, Season, Management, Property management, Renewable energy, Limited, S.A

HONG KONG, Sept 21, 2022 - (ACN Newswire) - The second industry forum (the "Forum") under the SME ESG Best Practices Recognition Programme ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").

Key Points: 
  • HONG KONG, Sept 21, 2022 - (ACN Newswire) - The second industry forum (the "Forum") under the SME ESG Best Practices Recognition Programme ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").
  • Dah Sing Bank, Limited ("Dah Sing Bank") is a wholly-owned subsidiary of Dah Sing Banking Group Limited (HKG:2356) which is listed on the Hong Kong Stock Exchange.
  • In addition to its Hong Kong banking operations, Dah Sing Bank also has wholly-owned subsidiaries including Dah Sing Bank (China) Limited, Banco Comercial de Macau, S.A., and OK Finance Limited.
  • Dah Sing Bank and Friends of the Earth (HK) Jointly Present:
    Industry Forums / Programme Application Opens: 27 June 2022 / 21 September 2022
    Online Questionnaire Completion & Supporting Documents Submission: Until 31 December 2022 / Until 28 February 2023

Forbion Co-leads $70 Million Financing of F2G to Advance Development and Commercialization of New Antifungal Agent Olorofim

Retrieved on: 
Thursday, August 4, 2022
Human, European Medicines Agency, United Nations Principles of Medical Ethics, Standard of care, BGV, ERP, LFA, Socially responsible investing, DVI, Patient, European Recovery Plan, QIDP, Marshall Plan, SOC, FDA, Disease, EIF, Infection, EUR, Inhalation, Investment, The Programme, Coccidioidomycosis, Health, Antifungal, EFSI, Mycosis, Mortality, Aspergillosis, Pharmaceutical industry, Aspergillus, Scopulariopsis

Forbion manages well over EUR 2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development.

Key Points: 
  • Forbion manages well over EUR 2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development.
  • Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
  • Olorofim has received orphan drug status from the European Medicines Agency for the treatment of invasive aspergillosis and invasive scedosporiosis.
  • Olorofim has also received orphan drug status from the FDA for the treatment of coccidioidomycosis scedosporiosis, and invasive aspergillosis.

Dah Sing Bank and Friends of the Earth (HK) Jointly Present Property and Construction Industry ESG Forum for SMEs

Retrieved on: 
Monday, June 27, 2022
Knowledge, Bank, HK, Carbon, Adoption, Senior, Corporate communication, Left, Hong Kong Stock Exchange, Friends of the Earth, Forum, ESG, Dah Sing Bank, Industry, Program, Mouth, Challenge, Awareness, Retail, BBS, Hong Kong residents, Investment, Partnership, The Programme, SME, CESGA, Environment, Goal, Survival, General manager, United Nations Sustainable Development Group, Corporate finance, Friends, Solution, Government, Guangdong-Hong Kong-Macau Greater Bay Area, Property management, Management, Renewable energy, Tutoring, S.A, Limited

HONG KONG, June 27, 2022 - (ACN Newswire) - The first industry forum ("the Forum") under the "SME ESG Best Practices Recognition Programme" ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").

Key Points: 
  • HONG KONG, June 27, 2022 - (ACN Newswire) - The first industry forum ("the Forum") under the "SME ESG Best Practices Recognition Programme" ("the Programme") took place today under the joint auspices of Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) ("FoE HK").
  • ESG implementation may become one of the ways for SMEs to overcome adversity in a down market.
  • Dah Sing Bank, Limited ("Dah Sing Bank") is a wholly-owned subsidiary of Dah Sing Banking Group Limited (HKG:2356) which is listed on the Hong Kong Stock Exchange.
  • In addition to its Hong Kong banking operations, Dah Sing Bank also has wholly-owned subsidiaries including Dah Sing Bank (China) Limited, Banco Comercial de Macau, S.A., and OK Finance Limited.

Dah Sing Bank and Friends of the Earth (HK) Jointly Present: The SME ESG Best Practices Recognition Programme

Retrieved on: 
Wednesday, June 8, 2022
SME, International Council for Game and Wildlife Conservation (CIC), Hong Kong Stock Exchange, UNSDG, Knowledge, ESG, Hotel manager, Development, Corporate communication, Bank, CEO, United Nations Sustainable Development Group, Environment, Awareness, Government, Carbon, Senior, The Programme, Investment, Solution, Retail, BEC, Dah Sing Bank, CMA, CIC, Face, Review, CESGA, Adoption, Friends of the Earth, Industry, Friends, HK, Guangdong-Hong Kong-Macau Greater Bay Area, Program, Management, Renewable energy, Tutoring, S.A, Limited

HONG KONG, June 8, 2022 - (ACN Newswire) - Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) have jointly launched the "SME ESG Best Practices Recognition Programme" ("the Programme") today.

Key Points: 
  • HONG KONG, June 8, 2022 - (ACN Newswire) - Dah Sing Bank, Limited ("Dah Sing Bank") and Friends of the Earth (HK) have jointly launched the "SME ESG Best Practices Recognition Programme" ("the Programme") today.
  • The Programme encourages SMEs to adopt best practices in environmental, social and governance (ESG), enhancing their competitiveness while achieving sustainable development.
  • Ms. Phoebe Wong, Deputy Chief Executive, Senior Executive Director, Group Head of Personal Banking of Dah Sing Bank, said, "Our Bank is committed to supporting SMEs.
  • Dah Sing Bank, Limited ("Dah Sing Bank") is a wholly-owned subsidiary of Dah Sing Banking Group Limited (HKG:2356) which is listed on the Hong Kong Stock Exchange.

Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund

Retrieved on: 
Thursday, October 14, 2021
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Scripps Research, The Programme, Degenerative disease, Disease, POC, Partner, Gastrointestinal tract, Therapy, Medication, Pharma, EIF, DVI, Marshall Plan, Precision medicine, Health, Patient, ERP, Biotechnology, Computational biology, Partner (business rank), ABC, BGV, Drug discovery, Alnylam Pharmaceuticals, EUR, Vertex Pharmaceuticals, European Recovery Plan, Liver, Senior, Socially responsible investing, CBO, Department, PFM Group, Eye, Investment, Executive, Central nervous system, Vertex, CFTR, Growth, Atlas, Atlas Venture, EFSI, LFA, Cystic fibrosis, Lists of diseases, Institute of Liver and Biliary Sciences, Company, Omega, Entrepreneurship, United Nations Principles of Medical Ethics, Pharmaceutical industry, Management, Aquaculture, Fine chemical, Rectify Pharmaceuticals, Inc. (“Rectify”), Atlas Venture, Omega Funds, Forbion, Longwood Fund, RECTIFY PHARMACEUTICALS, INC. (“RECTIFY”), ATLAS VENTURE, OMEGA FUNDS, FORBION, LONGWOOD FUND

Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.

Key Points: 
  • Rectify Pharmaceuticals, Inc. , (Rectify) a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics that restore ABC transporter function, today announced it has closed a $100 million Series A financing co-led by Atlas Venture, Omega Funds, Forbion, and Longwood Fund.
  • Rectify plans to use this financing to fund the company through its first human proof-of-concept (POC) studies.
  • We founded Rectify to deliver life-changing therapies to patients with serious genetic diseases, said Rajesh Devraj, Ph.D., President and Chief Executive Officer and venture partner with Atlas Venture.
  • Jonathan Moore, Ph.D., Chief Scientific Officer, founded Rectify with Atlas Venture in 2020.

Covicept Therapeutics initiates a Phase 2 clinical study with PJS-539, an oral small molecule for the treatment of patients with COVID-19 (SARS-CoV-2)

Retrieved on: 
Wednesday, October 6, 2021
GMP, EUR, Therapy, Socially responsible investing, Vaccine, EFSI, RNA, Pandemic, European Recovery Plan, Health, Hospital, LFA, Orthornavirae, Patient, MD, ERP, Virus, DVI, The Programme, Dengue fever, Medicine, Investor, Program, United Nations Principles of Medical Ethics, Entrepreneurship, COVID-19, Pneumonia, Human, Severe acute respiratory syndrome coronavirus 2, Tissue, Infection, Degenerative disease, Safety, Viral load, EIF, Marshall Plan, Fibrosis, Investment, BGV, Paulo, Pharmaceutical industry

PSJ-539 has the potential to become a best-in-class small molecule for the treatment of COVID-19 patients and also has potential as a broad-spectrum antiviral drug targeting RNA viruses.

Key Points: 
  • PSJ-539 has the potential to become a best-in-class small molecule for the treatment of COVID-19 patients and also has potential as a broad-spectrum antiviral drug targeting RNA viruses.
  • This multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate safety and efficacy of PJS-539 in patients recently diagnosed with COVID-19.
  • The unique mechanism of action of PSJ-539 may prevent or minimize the development of resistance to vaccines and anti-viral medications.
  • Covicept is developing PSJ-539, a small molecule that inhibits attachment, infection and replication of SARS-CoV-2 and other RNA viruses.

Launch of Oxitope Pharma, a biopharmaceutical start-up dedicated to the discovery and development of antibody-based medicines for the treatment of diseases caused by oxidative stress

Retrieved on: 
Thursday, September 16, 2021
OS Fund, DVI, Degenerative disease, Knowledge, Investment, EFSI, The Programme, Inflammation, Drug discovery, CEO, University, Oxidative stress, Technology, Antibody, Health, Patient, Socially responsible investing, United Nations Principles of Medical Ethics, Atherosclerosis, LFA, Mortality, European Recovery Plan, BGV, Epitope, UCSD, Therapy, Marshall Plan, EIF, University of California, San Diego, Vincent, EUR, Cell death, ERP, Human, Disease, Research, Pharmaceutical industry

Based on a body of research spanning over 40 years published in a range of high profiles scientific papers authored by Profs.

Key Points: 
  • Based on a body of research spanning over 40 years published in a range of high profiles scientific papers authored by Profs.
  • Witztum and Tsimikas, Oxitope is dedicated to the discovery and development of medicines that prevent, halt, or reverse acute and chronic diseases driven by inflammation and cell death as a result of oxidative stress.
  • Founded in 2020, Oxitope Pharma B.V. is a Dutch biopharmaceutical start-up dedicated to the discovery and development of medicines for the treatment of inflammatory, fibrotic and cardiovascular diseases caused by oxidative stress.
  • Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.